Ostin s.r.o.

The research program at Ostin s.r.o. focuses on Cardiovascular Diseases, investigating both Atherosclerotic cardiovascular disease and the role of obesity in heart health. Clinical studies aim to test innovative therapies that could lower cardiovascular morbidity and mortality.

• Evaluation of maridebart cafraglutide as an adjunct to standard care
• Assessment of olpasiran for lipoprotein(a) reduction
• Prevention of first major cardiovascular events in high‑risk patients
• Impact of weight management on ASCVD outcomes

With two active trials and a dedicated investigator, the site located in Ostrava, Czechia, is contributing to the development of next‑generation cardiovascular treatments.